Akari Therapeutics, Plc
AKTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -86,139.65% | -107,603.99% | -73,281.76% | -29,273.12% |
| EV / EBITDA | -0.03 | 0.23 | 0.57 | 0.54 |
| Quality | ||||
| ROIC | -63.82% | 7,338.86% | -1,289.11% | -309.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 1.64 | 1.21 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 23.61% | 23.59% | -14.10% | -11.19% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.23 | 0.57 | 0.54 |
| Interest Coverage | 88.70 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |